CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • ÀüÈ«Àç
  • ¾Ï¼¾ÅÍÀå
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : °£¾Ï/Ãé´ãµµ¾Ï
  • Á÷ À§: ºÎ±³¼ö(¾Ï¼¾ÅÍÀå)
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ
173 (±¹³»)KCI Àç¹ßÇÑ ÀڱðæºÎ¾Ï¿¡¼­ ÀüÀ̼º °©»ó¼±¾Ï
172 (±¹¿Ü)SCIE Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma
171 (±¹¿Ü)SCI Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RETRearranged Lung Adenocarcinoma
170 (±¹¿Ü)SCI Efficacy and Safety of Edoxaban for Treatment of Venous Thromboembolism: A Subanalysis of East Asian Patients in the Hokusai-VTE Trial.
169 (±¹¿Ü)SCI Congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) caused by novel ADAMTS13 mutations.
168 (±¹¿Ü)SCIE 3¡¯-UTR polymorphisms in the miRNA machinery genes DROSHA, DICER1, RAN, and XPO5 are associated with colorectal cancer risk in a Korean population
167 (±¹¿Ü)SCIE Genetic variants in 3¡¯-UTRs of methylenetetrahydrofolate reductase (MTHFR) predict colorectal cancer susceptibility in Korean
166 (±¹¿Ü)SCI An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer
165 (±¹¿Ü)SCI Long-term Clinical Outcomes of Splanchnic Vein Thrombosis: Results of an International Registry.
164 (±¹³»)SCIE Predisposing roles of paraoxonase-1 genetic variants in Korean ischemic stroke patients
ÀÌÀüÆäÀÌÁö À̵¿ 11 12 13 14 15 16 17 18 19 20 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729